Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05378425 · ClinicalTrials.gov registry record · Phase 1
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
A Phase 1 study of Cancer and Advanced Solid Tumor, sponsored by Nectin Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 6
- Study locations
NCT05378425 is a Phase 1 study of Cancer and Advanced Solid Tumor that is actively recruiting participants, run by Nectin Therapeutics. The registered enrollment target is 90 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT05378425, a Phase 1 study of Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by Nectin Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally advanced or metastatic).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG NTX-1088
Study Locations (6)
Other
- Hadassah Medical Center - Jerusalem
- Sheba Medical Center - Ramat Gan
- Maria Skłodowska-Curie National Research Institute of Oncology - Warsaw
California
- City of Hope - Duarte
Louisiana
- Ochsner Clinic Foundation - New Orleans
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05378425
The ClinicalTrials.gov registry entry for NCT05378425 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Nectin Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05378425 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05378425 about?
NCT05378425 is a clinical study titled "A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab". This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally ad...
What is the current status of trial NCT05378425?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2022-09-01. Estimated completion is 2026-12.
What conditions does trial NCT05378425 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor, Tumor, Solid.
What interventions are being tested in trial NCT05378425?
The interventions under investigation include: Pembrolizumab (DRUG), NTX-1088 (DRUG).
Who is sponsoring clinical trial NCT05378425?
This trial is sponsored by Nectin Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05378425 being conducted?
This trial has 6 study locations across California, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.